GW-0742 sulfoxide | PPAR δ agonist

MedKoo Cat#: 574720 | Name: GW-0742 sulfoxide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GW-0742 sulfoxide is a small molecule agonist of the human Peroxisome Proliferator-Activated Receptor δ (PPAR δ).

Chemical Structure

GW-0742 sulfoxide

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 574720

Name: GW-0742 sulfoxide

CAS#: N/A

Chemical Formula: C21H17F4NO5S2

Exact Mass: 503.0484

Molecular Weight: 503.48

Elemental Analysis: C, 50.10; H, 3.40; F, 15.09; N, 2.78; O, 15.89; S, 12.74

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

GW-0742 sulfoxide, GW0742 sulfoxide, GW 0742 sulfoxide; GW0742 Sulfone;

IUPAC/Chemical Name

2-(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)methyl)sulfonyl)-2-methylphenoxy)acetic acid

InChi Key

FXHVSXWZVCKELY-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H17F4NO5S2/c1-11-7-14(4-6-17(11)31-9-19(27)28)33(29,30)10-18-12(2)26-20(32-18)13-3-5-15(16(22)8-13)21(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,28)

SMILES Code

CC1=C(OCC(O)=O)C=CC(S(CC2=C(C)N=C(C3=CC(F)=C(C(F)(F)F)C=C3)S2)(=O)=O)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

GW-0742 sulfoxide is a small molecule agonist of the human Peroxisome Proliferator-Activated Receptor δ (PPAR δ).

In vitro activity:

Treatment with 10 µmol/L of GW0742 significantly reduced expression of TXNIP (Figure 6C,D, P < 0.01), which was accompanied by decreased expression of secreted pro‐inflammatory cytokines IL‐1β and TNF‐α (Figure 6C,D, P < 0.05), suggesting that GW0742 can reduce inflammation in PC12 cells subjected to OGD. Reference: J Cell Mol Med. 2020 Nov;24(21):12318-12330. https://pubmed.ncbi.nlm.nih.gov/33034416/

In vivo activity:

Since neural stem cells have been shown to use FAO to support neurogenic activity, and neurogenesis is linked with amelioration of cognitive deficits, this study assessed whether GW0742 treatment enhanced the production of newborn neurons as detected by DCX staining in the hippocampi of the GW0742 treated APP/PS1 mice. Although the number of DCX positive cells was very low in the 12-month-old APP/PS1 mice, it was slightly, yet significantly, increased in the treated mice compared to their vehicle treated controls (t(15) = 2.3, p = .04, unpaired t test, Figure 4a,b). Reference: Glia. 2019 Jan;67(1):146-159. https://pubmed.ncbi.nlm.nih.gov/30453390/

Preparing Stock Solutions

The following data is based on the product molecular weight 503.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Gamdzyk M, Doycheva DM, Kang R, Tang H, Travis ZD, Tang J, Zhang JH. GW0742 activates miR-17-5p and inhibits TXNIP/NLRP3-mediated inflammation after hypoxic-ischaemic injury in rats and in PC12 cells. J Cell Mol Med. 2020 Nov;24(21):12318-12330. doi: 10.1111/jcmm.15698. Epub 2020 Oct 9. PMID: 33034416; PMCID: PMC7686982. 2. Konttinen H, Gureviciene I, Oksanen M, Grubman A, Loppi S, Huuskonen MT, Korhonen P, Lampinen R, Keuters M, Belaya I, Tanila H, Kanninen KM, Goldsteins G, Landreth G, Koistinaho J, Malm T. PPARβ/δ-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1ΔE9 astrocytes. Glia. 2019 Jan;67(1):146-159. doi: 10.1002/glia.23534. Epub 2018 Nov 19. PMID: 30453390; PMCID: PMC7526864. 3. Ozawa C, Horiguchi M, Akita T, Oiso Y, Abe K, Motomura T, Yamashita C. Pulmonary Administration of GW0742, a High-Affinity Peroxisome Proliferator-Activated Receptor Agonist, Repairs Collapsed Alveoli in an Elastase-Induced Mouse Model of Emphysema. Biol Pharm Bull. 2016;39(5):778-85. doi: 10.1248/bpb.b15-00909. PMID: 27150147.

In vitro protocol:

In vivo protocol:

1. Konttinen H, Gureviciene I, Oksanen M, Grubman A, Loppi S, Huuskonen MT, Korhonen P, Lampinen R, Keuters M, Belaya I, Tanila H, Kanninen KM, Goldsteins G, Landreth G, Koistinaho J, Malm T. PPARβ/δ-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1ΔE9 astrocytes. Glia. 2019 Jan;67(1):146-159. doi: 10.1002/glia.23534. Epub 2018 Nov 19. PMID: 30453390; PMCID: PMC7526864. 2. Ozawa C, Horiguchi M, Akita T, Oiso Y, Abe K, Motomura T, Yamashita C. Pulmonary Administration of GW0742, a High-Affinity Peroxisome Proliferator-Activated Receptor Agonist, Repairs Collapsed Alveoli in an Elastase-Induced Mouse Model of Emphysema. Biol Pharm Bull. 2016;39(5):778-85. doi: 10.1248/bpb.b15-00909. PMID: 27150147.

1.Konttinen H, Gureviciene I, Oksanen M, et al. PPARβ/δ-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1ΔE9 astrocytes. Glia. 2019;67(1):146-159. doi:10.1002/glia.23534 2. Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Alshammari MA, Attia SM. The PPARδ agonist GW0742 restores neuroimmune function by regulating Tim-3 and Th17/Treg-related signaling in the BTBR autistic mouse model. Neurochem Int. 2018;120:251-261. doi:10.1016/j.neuint.2018.09.006